Loading
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Latest quote
$2.22
−$0.05 · -2.20%
After-hours
$2.22
$0.00 · 0.00%
Oct 8, 4:04 PM ET
Regular session · ET · Market data may be delayed.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Day range
Current $2.22
52-week range
Current $2.22
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
36
Expensive
Sentiment
49
Mixed
Risk
53
Elevated Risk
Momentum
79
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Day range
Current $2.22
52-week range
Current $2.22
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 9.19M USD | — | 5.87M USD | — | — |
| Gross profit | −9.19M USD | — | −5.87M USD | — | — |
| Research and development | 90.43M USD | 96.74M USD | 90.9M USD | 90.9M USD | 63.41M USD |
| Selling, general, and administrative | 31.57M USD | 31.45M USD | 34.88M USD | 28.06M USD | 23.02M USD |
| Operating expenses | 112.01M USD | 128.19M USD | 125.78M USD | 118.96M USD | 86.43M USD |
| Interest income | 15.49M USD | 19.32M USD | 14.11M USD | 5.59M USD | 370K USD |
| Interest expense | — | — | — | 5.59M USD | — |
| Depreciation and amortization | 9.19M USD | 9.15M USD | 5.87M USD | 2.64M USD | 1.76M USD |
| Operating income | −121.21M USD | −128.19M USD | −131.65M USD | −118.96M USD | −86.43M USD |
| Net income | −104.08M USD | −108.79M USD | −117.5M USD | −113.84M USD | −86.08M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.00
305.41% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.25M0.00%2.3T USD0.03%$379.55-0.39%
iShares Russell 2000 ETFIWM2.65M0.00%78.56B USD0.19%$277.63-0.03%
Vanguard Extended Market ETFVXF1.62M0.00%95.4B USD0.05%$233.16-0.14%
Vanguard Russell 2000 ETFVTWO694.19K0.00%18B USD0.06%$112.1-0.10%
Dimensional - US Small Cap ETFDFAS470.28K0.00%33.66B USD0.31%$78.14+0.28%
iShares Micro-Cap ETFIWC323.25K0.02%1.33B USD0.60%$182.68-0.37%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM250K0.21%116.75M USD0.73%$15.91-0.38%
Invesco RAFI US 1500 Small-Mid ETFPRFZ228.98K0.01%2.68B USD0.36%$52.82+0.17%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
